Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AYLANASDAQ:CYTHNYSE:JATTNASDAQ:SCLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYLAAyala Pharmaceuticals$0.50$0.48$0.36▼$7.31$7.46M1.9876,300 shsN/ACYTHCyclo Therapeutics$0.72$0.73$0.55▼$1.62$23.72M-0.57441,729 shsN/AJATTJATT Acquisition$1.37-4.9%$1.28$7.80▼$12.38$140.76MN/A41,322 shs163,088 shsSCLXScilex$4.67+5.4%$8.92$3.60▼$80.50$32.50M1.0447,659 shs122,952 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYLAAyala Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CYTHCyclo Therapeutics0.00%0.00%0.00%-9.93%-42.81%JATTJATT Acquisition0.00%+11.38%+1.11%-20.35%-68.93%SCLXScilex0.00%-22.43%-45.16%-70.99%-84.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACYTHCyclo Therapeutics2.7848 of 5 stars3.25.00.00.00.03.30.0JATTJATT AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ASCLXScilex2.9869 of 5 stars3.35.00.00.02.81.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYLAAyala Pharmaceuticals 0.00N/AN/AN/ACYTHCyclo Therapeutics 2.33Hold$0.9531.83% UpsideJATTJATT Acquisition 0.00N/AN/AN/ASCLXScilex 2.60Moderate Buy$455.009,643.04% UpsideCurrent Analyst Ratings BreakdownLatest AYLA, SCLX, CYTH, and JATT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2025SCLXScilexD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/11/2025SCLXScilexD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/2/2025SCLXScilexD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$770.00 ➝ $630.002/28/2025SCLXScilexD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$770.00 ➝ $770.00(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYLAAyala Pharmaceuticals$3.51M2.13N/AN/A$2.45 per share0.21CYTHCyclo Therapeutics$870.73K27.24N/AN/A$0.21 per share3.43JATTJATT AcquisitionN/AN/A$0.05 per share27.08($0.53) per shareN/ASCLXScilex$56.59M0.57N/AN/A($1.10) per share-4.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYLAAyala Pharmaceuticals-$40.25M-$2.52N/AN/AN/A-2,341.69%-182.13%-139.83%N/ACYTHCyclo Therapeutics-$20.06M-$0.90N/AN/AN/A-2,847.19%N/A-307.16%5/13/2025 (Estimated)JATTJATT Acquisition$6.85MN/A0.00∞N/AN/A-49.58%2.84%N/ASCLXScilex-$114.33M-$29.02N/AN/AN/A-159.10%N/A-93.65%5/12/2025 (Estimated)Latest AYLA, SCLX, CYTH, and JATT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025N/ASCLXScilex-$0.09N/AN/AN/A$17.79 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/ACYTHCyclo TherapeuticsN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/ASCLXScilexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYLAAyala PharmaceuticalsN/A2.282.28CYTHCyclo TherapeuticsN/A0.170.16JATTJATT AcquisitionN/A0.150.15SCLXScilexN/A0.140.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYLAAyala Pharmaceuticals22.10%CYTHCyclo Therapeutics68.55%JATTJATT Acquisition47.97%SCLXScilex69.67%Insider OwnershipCompanyInsider OwnershipAYLAAyala Pharmaceuticals3.60%CYTHCyclo Therapeutics29.78%JATTJATT Acquisition20.00%SCLXScilex7.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAYLAAyala Pharmaceuticals3514.82 million14.29 millionNot OptionableCYTHCyclo Therapeutics932.92 million23.12 millionNo DataJATTJATT Acquisition317.25 million13.80 millionNot OptionableSCLXScilex806.96 million222.07 millionOptionableAYLA, SCLX, CYTH, and JATT HeadlinesRecent News About These CompaniesScilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025April 22, 2025 | globenewswire.comScilex (NASDAQ:SCLX) Reaches New 1-Year Low - Should You Sell?April 19, 2025 | marketbeat.comScilex (NASDAQ:SCLX) Trading Down 12.2% - Here's What HappenedApril 18, 2025 | marketbeat.comScilex (NASDAQ:SCLX) Sees Large Volume Increase - Here's WhyApril 17, 2025 | marketbeat.comScilex Gets Orphan Drug Designation for Its Version of ColchicineApril 17, 2025 | marketwatch.comScilex treatment of pericarditis granted FDA orphan designationApril 17, 2025 | markets.businessinsider.comScilex confirms FDA awards orphan drug designation for colchicineApril 17, 2025 | markets.businessinsider.comScilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of PericarditisApril 16, 2025 | globenewswire.comScilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®'s Acute Treatment of Migraine With or Without Aura in CanadaApril 15, 2025 | globenewswire.comScilex announces 1-for-35 reverse stock splitApril 12, 2025 | markets.businessinsider.comD. Boral Capital Downgrades Scilex Holding (SCLX)April 12, 2025 | msn.comScilex downgraded to Hold from Buy at D. Boral CapitalApril 11, 2025 | msn.comScilex Holding Company Announces 1-for-35 Reverse Stock SplitApril 11, 2025 | globenewswire.comD. Boral Capital Lowers Scilex (NASDAQ:SCLX) Price Target to $18.00April 4, 2025 | marketbeat.comScilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against AvevaMarch 26, 2025 | globenewswire.comScilex Holding Company Announces Change of Record Date for Preferred Stock DividendMarch 12, 2025 | nasdaq.comScilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025March 10, 2025 | globenewswire.comScilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025January 31, 2025 | globenewswire.comWhy Scilex Holding Co (SCLX) Stock is Currently 3.30% Above from Its 20-Day SMA?January 28, 2025 | bovnews.comScilex regains compliance with Nasdaq listing rulesJanuary 21, 2025 | markets.businessinsider.comScilex to file SNDA with FDA for ELYXYBJanuary 21, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAYLA, SCLX, CYTH, and JATT Company DescriptionsAyala Pharmaceuticals NASDAQ:AYLAAyala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.Cyclo Therapeutics NASDAQ:CYTH$0.72 0.00 (0.00%) As of 03/26/2025Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.JATT Acquisition NYSE:JATT$1.37 -0.07 (-4.86%) As of 04/25/2025JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.Scilex NASDAQ:SCLX$4.67 +0.24 (+5.42%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$4.68 +0.01 (+0.21%) As of 04/25/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
